Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AVIR with free AI briefings, catalyst countdowns, and dilution alerts.

AVIR · Atea Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$191.2M Cash on Hand
17.4mo Cash Runway
Follow AVIR by email Get an email when AVIR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AVIR, unsubscribe in one click. Privacy

📣 What AVIR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bemnifosbuvir-Ruzasvir HEPATITIS C VIRUS CHRONIC INFECTION Phase 3 · NCT06868264 Completed
Bemnifosbuvir Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) Phase 3 · NCT05629962 Completed
Sofosbuvir-Velpatasvir HEPATITIS C VIRUS CHRONIC INFECTION Phase 3 · NCT06868264 Completed
Bemnifosbuvir Sulfate (AT-527) COVID-19 Phase 3 · NCT04889040 Terminated
AT-777 Hepatitis C Phase 1/2 · NCT04309734 Withdrawn
Daclatasvir Hepatitis C Phase 2 · NCT04019717 Completed
AT-752 Dengue Fever Phase 2 · NCT05466240 Terminated
Ruzasvir Chronic Hepatitis C Virus Phase 2 · NCT05904470 Completed
Moxifloxacin Healthy Volunteer Study Phase 1 · NCT05905484 Completed
Rosuvastatin Healthy Volunteer Study Phase 1 · NCT05154123 Completed
Ethinyl Estradioll/Levonorgestrel (EE/LNG) Healthy Volunteer Study Phase 1 · NCT07272889 Completed
Methadone Healthy Volunteer Study Phase 1 · NCT07314346 Completed
Period 1: AT-527 550 mg Healthy Volunteer Study Phase 1 · NCT04784000 Completed
Period 2: carbamazepine Healthy Volunteer Study Phase 1 · NCT04784000 Completed
Treatment A-Bemnifosbuvir/Ruzasvir FDC… Healthy Volunteer Study Phase 1 · NCT07007806 Completed
Naloxone Healthy Volunteer Study Phase 1 · NCT07314346 Completed

Also used in these trials (approved or third-party drugs, not AVIR's own candidates): Omeprazole, Carbamazepine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AVIR holds $191.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $33M/quarter from operations, an estimated runway of 17.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVIR files for a raise →

👥 Who Owns AVIR

Insiders 14.4% Other 5%+ holders 15.7% Institutions (181 holders) 69.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 11,950,772 14.88% 2026-03-31
Jean-Pierre Sommadossi
President, CEO, and Chairman, Director · +440,000 options
Insider 9,080,450 11.31% 2026-09-30
Leonard Braden Michael 5%+ holder (13G) 7,810,000 9.73% 2025-12-31
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13G) 4,814,700 6.00% 2026-10-06
Andrea Corcoran
Chief Financial Officer, Executive Vice · +380,000 options
Insider 823,576 1.03% 2026-03-11
Franklin M Berger
Director · +146,800 options
Insider 536,097 0.67% 2026-06-18
John Vavricka
Chief Commercial Officer · +252,320 options
Insider 165,102 0.21% 2026-01-31
Bruno Lucidi
Director · +105,600 options
Insider 142,350 0.18% 2026-06-18
Janet MJ Hammond
Chief Development Officer · +377,000 options
Insider 127,665 0.16% 2026-01-31
Bruce Polsky
Director · +105,600 options
Insider 124,806 0.16% 2026-06-18
Polly A. Murphy
Director · +105,600 options
Insider 121,745 0.15% 2026-06-18
Maria Arantxa Horga
Chief Medical Officer · +366,300 options
Insider 96,086 0.12% 2026-01-31

Share count 80,304,145 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AVIR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVIR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.